Cantargia | Evaluate

August 15, 2022

Canakinumab’s cancer career ends with a whimper

Novartis's latest failure, in adjuvant lung cancer, heaps more doubt on a rival approach from Cantargia.

October 25, 2021

Novartis won’t can canakinumab

March 09, 2021

Cana can’t – can Cantargia?

February 12, 2021

Novartis’s canakinumab cancer test approaches

Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?